Your search for oral corticosteroids returned 248 results

Your search for oral corticosteroids returned 248 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Orphan Drug Designation Granted for Treatment after Radiological Disaster

Soligenix announced that the FDA has granted Orphan Drug Designation to OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP) for the prevention of death following a potentially lethal dose of total body irradiation (TBI) during or after a radiation disaster.
News

Emend for Oral Suspension Approved by the FDA

The FDA has approved the New Drug Application (NDA) for Emend (aprepitant; Merck) for oral suspension for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients aged ≥6 months old.
Drugs in the Pipeline

Fast Track Designation Granted for OrbeShield in GI ARS

Soligenix announced today that the FDA has designated its OrbShield (oral beclomethasone 17, 21-dipropionate or oral BDP) development program for the treatment of Gastrointestinal Acute Radiation Syndrome (GI ARS), for Fast Track review.
News

Flo-Pred approved for asthma

Taro Pharmaceuticals has received FDA approval for Flo-Pred (prednisolone acetate oral suspension), a prescription corticosteroid for the treatment of asthma, certain allergic and dermatologic conditions, and a variety of other indications.
Slideshow

Clinical Challenge: A Burning, Acneiform Facial Eruption

A white 24-year-old female presents with erythematous, papulopustular patches of skin in a muzzle-like distribution surrounding the mouth, chin, and glabellar region. Her history includes a variety of topical antibiotics that were previously successful with complete resolution; however, at present the lesions are persisting despite the treatment.